Alan is an experienced, oncology focused, biotech founder, entrepreneur and innovative leader focused on company ideation and strategic growth through capital raises, non-dilutive collaborative partnerships and value enhancing asset acquisitions. A mission ‘driven’, patient-centric leader with an unwavering commitment to build, focus and accelerate the advancement of innovative first-in-human, first-in-class therapies that impact patients’ lives.

As an oncology innovator Alan co-founded and served as President and CEO of HiberCell, a company focused on leveraging multi-omic data to target the stress response pathways of dormant disseminated tumor cells with a goal of preventing cancer relapse. Under his leadership, HiberCell launched in 2019 with a $61 million USD, Series A and ultimately raised more than $250M USD. Prior to co-founding HiberCell, Alan held C-suite executive roles at Warp Drive Bio, Inc., Synta Pharmaceuticals, and was a Vice President of Oncology at Eli Lilly and Company, where he advanced several drug discovery and development programs.

Prior to his career in biopharma and biotechnology, Alan served as an Assistant Professor and Adjunct Assistant Professor at Harvard Medical School, with a focus on computational drug discovery and target validation. He holds a PhD in Biochemistry from Canada’s Western University.

Jon is a biochemist and cell biologist with 22 years of scientific leadership experience in industry, primarily in oncology. He is an Operating Partner at Advent Life Sciences where he co-founded both Epitopea and the remyelination start-up Pheno Therapeutics, serving both companies as their first CEO.

Prior to joining Advent, Jon was CSO of gene editing tools and services company, Horizon Discovery, and Head of Biology at Vernalis Research. At both organisations his focus was on leading drug discovery projects, early-stage discovery collaborations and in and out-licensing key technologies.

Jon also has extensive postdoctoral experience working with Tim Hunt at Cancer Research UK and Sally Kornbluth at Duke University. He holds a PhD from the University of Newcastle upon Tyne.

Steven brings over 20 years of business development experience in industry and non-profit organisations across a variety of fields, including oncology, vaccines, and CNS-related indications.

Steven previously held several business development leadership roles, where he successfully negotiated numerous strategic transactions and managed alliances with a wide range of biopharmaceutical companies, including BMS, Ipsen, Abbvie, Merck, Pfizer, Roche, Nippon Shinyaku, Grunenthal, AstraZeneca, Domain Therapeutics, and Medigene.

Steven holds a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.

Trained as a hematologist and an immunogeneticist, Claude has been a Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal since 2005 and is in charge of its immunobiology research laboratory.

He is a Professor in the Faculty of Medicine of the Université de Montréal and was a practicing clinician until 2018, at the Maisonneuve-Rosemont Hospital, where he created the histocompatibility laboratory and founded the bone marrow transplant unit.

Member of the Canadian Academy of Health Sciences, Claude has received the Acfas Léo-Pariseau prize (2011), the Michel-Sarrazin Award (2015) of the Club de recherches cliniques du Québec and the Bernhard Cinader Award of the Canadian Society for Immunology (2017).

Pierre began his career with the National Research Council of Canada as a protein chemistry Investigator. Between 2001 and 2004, he operated the Protein Analysis Department at Caprion Pharmaceuticals.

He then joined the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal where he operates the Proteomics Research Unit and the Center for Advanced Proteomics and Chemogenomics Analyses (CAPCA).

Pierre is also a Professor in the Department of Chemistry and an Accredited Member of the Department of Biochemistry of the Faculty of Medicine at Université de Montréal.

Michael is an internationally recognized expert in T cell therapy and immunotherapy. Over his 28-year career, he has co-authored over 85 peer-reviewed manuscripts and book chapters, and holds 26 issued patents in the fields of cell therapy, immunotherapy, and vaccines.

Michael is a member of several Corporate and Scientific Advisory Boards for both public and private biopharmaceutical companies and is currently Founder and Managing Director at Next Pillar Consulting. Michael also serves as Senior Venture Partner and Head of Cell Therapy for Orange Grove Bio. In addition to his board and SAB responsibilities, Michael actively serves as an advisory member for international immunotherapy consortia and societies.

Previous C-suite and executive roles include positions at cTRL-Therapeutics, ArsenalBio, Janssen, and Eli Lilly and Company. During Michael’s tenure in biopharma he established and led internal programs on cancer vaccines targeting “dark matter”.

During his academic career, Michael founded and directed translational research laboratories at the University of Pennsylvania and City of Hope. At UPenn his lab developed many of the operational principles that have supported the translational understanding of cell and immune- based therapies, and he is a co-inventor of the key technologies that led to the approval of Kymriah by Novartis. He holds a PhD from the University of Minnesota and completed post-doctoral training at the Fred Hutchinson Cancer Research Center.